Financial Instruments (Details 2) (Fair Value, Inputs, Level 3 [Member], USD $) In Millions, unless otherwise specified			3 Months Ended	9 Months Ended
Mar. 29, 2014	Jun. 29, 2013	Mar. 29, 2014 Portion of contingency related to a product [Member] Fera Pharmaceuticals, LLC [Domain]	Dec. 28, 2013 Portion of contingency related to a product [Member] Fera Pharmaceuticals, LLC [Domain]	Mar. 29, 2014 Portion of contingency related to a product [Member] Fera Pharmaceuticals, LLC [Domain]	Jun. 17, 2013 Portion of contingency related to a product [Member] Fera Pharmaceuticals, LLC [Domain]	Jun. 17, 2013 Indemnification Agreement [Member] Fera Pharmaceuticals, LLC [Domain]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance as of June 29, 2013	$ 23.0	$ 22.2	$ 13.1			$ 18.0	$ 4.2
Writedown of Fera contingent consideration			5.7	(4.9)	0.8
Balance as of December 28, 2013	$ 23.0	$ 22.2	$ 18.8	$ 13.1	$ 18.8	$ 18.0	$ 4.2

The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4845-128472

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 55

-Paragraph 37

-URI http://asc.fasb.org/extlink&oid=25498275&loc=d3e2207-128464

Name:	us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant